Disease · MONDO_0005083
Comparisons in its trials192
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 20 of 192
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Treatment Period 2: Group 1 vs Treatment Period 2: Group 2: Maintenance of PASI 90 Response at Week 52 in Participants With a PASI 90 Response at Week 24 | 552 of 644 | 496 of 662 | 1,306 | NCT02409667 | Trial comparisons |
| Secukinumab 300mg (2 x 150 mg) vs Ustekinumab 2 x 45mg or 90mg: Participants Who Achieved Psoriasis Area and Severity Index (PASI) 100 Response at Week 12 | 210 of 550 | 111 of 552 | 1,102 | NCT02826603 | Trial comparisons |
| Secukinumab 300mg (2 x 150 mg) vs Ustekinumab 2 x 45mg or 90mg: Participants With IGA Mod 2011 0 or 1 at 16 Weeks | 432 of 550 | 326 of 552 | 1,102 | NCT02826603 | Trial comparisons |
| Secukinumab 300mg (2 x 150 mg) vs Ustekinumab 2 x 45mg or 90mg: Participants Who Achieved Psoriasis Area and Severity Index (PASI) 75 Response at Week 4 | 221 of 550 | 90 of 552 | 1,102 | NCT02826603 | Trial comparisons |
| Secukinumab 300mg (2 x 150 mg) vs Ustekinumab 2 x 45mg or 90mg: Participants Who Achieved Psoriasis Area and Severity Index (PASI) 75 Response at Week 16 | 506 of 550 | 441 of 552 | 1,102 | NCT02826603 | Trial comparisons |
| Secukinumab 300mg (2 x 150 mg) vs Ustekinumab 2 x 45mg or 90mg: Participants Who Achieved Psoriasis Area and Severity Index (PASI) 100 Response at Week 16 | 250 of 550 | 147 of 552 | 1,102 | NCT02826603 | Trial comparisons |
| Secukinumab 300mg (2 x 150 mg) vs Ustekinumab 2 x 45mg or 90mg: Participants Who Achieved Psoriasis Area and Severity Index (PASI) 75 Response at Week 12 | 484 of 550 | 409 of 552 | 1,102 | NCT02826603 | Trial comparisons |
| Secukinumab 300mg (2 x 150 mg) vs Ustekinumab 2 x 45mg or 90mg: Participants Who Achieved Psoriasis Area and Severity Index (PASI) 90 Response at Week 16 | 423 of 550 | 299 of 552 | 1,102 | NCT02826603 | Trial comparisons |
| Secukinumab 300mg (2 x 150 mg) vs Ustekinumab 2 x 45mg or 90mg: Participants Who Achieved Psoriasis Area and Severity Index (PASI) 90 Response at Week 12 | 366 of 550 | 265 of 552 | 1,102 | NCT02826603 | Trial comparisons |
| Secukinumab 300mg (2 x 150 mg) vs Ustekinumab 2 x 45mg or 90mg: Participants With IGA Mod 2011 0 or 1 at Week 12 | 397 of 550 | 306 of 552 | 1,102 | NCT02826603 | Trial comparisons |
| Secukinumab 300mg (2 x 150 mg) vs Ustekinumab 2 x 45mg or 90mg: Participants Who Achieved Psoriasis Area and Severity Index (PASI) 90 Response at Week 52 | 402 of 550 | 330 of 552 | 1,102 | NCT02826603 | Trial comparisons |
| Etanercept BIW/QW vs Etanercept QW/QW: Number of Patients Achieving Clear or Almost Clear on Physician Global Assessment (PGA) of Psoriasis | 176 of 379 | 119 of 373 | 752 | NCT00245960 | Trial comparisons |
| Adalimumab + Placebo vs Adalimumab + Calcipotriol/Betamethasone: serious adverse events | 15 of 364 | 16 of 366 | 730 | NCT00574249 | Trial comparisons |
| Topical/Traditional vs Adalimumab: deaths from any cause | 0 of 330 | 1 of 328 | 658 | NCT01387815 | Trial comparisons |
| Topical/Traditional vs Adalimumab: serious adverse events | 2 of 330 | 23 of 328 | 658 | NCT01387815 | Trial comparisons |
| Humira (Adalimumab) vs CHS-1420: Difference Between the Percentage of Subjects in Each Treatment Group Achieving a 75% Improvement in Psoriasis Area and Severity Index (PASI-75) at Week 12 | 203 of 271 | 211 of 274 | 545 | NCT02489227 | Trial comparisons |
| Enbrel (Etanercept) vs CHS-0214: serious adverse events | 10 of 260 | 7 of 261 | 521 | NCT02134210 | Trial comparisons |
| Tapinarof (DMVT-505) Cream Group vs Vehicle Cream Group: deaths from any cause | 0 of 343 | 0 of 172 | 515 | NCT03983980 | Trial comparisons |
| Tapinarof (DMVT-505) Cream Group vs Vehicle Cream Group: serious adverse events | 7 of 343 | 0 of 172 | 515 | NCT03983980 | Trial comparisons |
| Tapinarof (DMVT-505) vs Vehicle Cream: deaths from any cause | 0 of 340 | 0 of 170 | 510 | NCT03956355 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0005083/comparisons